Protocol Ledger

NCT05126719 · Phase II · ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Interventional Phase II clinical trial protocol NCT05126719 sponsored by Lepu Biopharma Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-06 Enrollment: 238 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05126719
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)238 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05126719
Protocol FieldVerified Registry Value
NCT IdentifierNCT05126719
Consolidated Lead SponsorLepu Biopharma Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment238 participants (ESTIMATED)
Registered Start Date2023-04-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05126719
Hospital Research SiteLocationSite Profile
Peking University Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Chongqing University Cancer HospitalChongqing, ChinaOpen Hospital Dossier ->
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->
Sun Yat-sen University Cancer CenterGuangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI